Fuke Qianjin Combined with Antibiotic Therapy for Pelvic Inflammatory Disease: A Systematic Review and Meta-Analysis

Abstract EN

Background.

Pelvic inflammatory disease (PID) without timely and proper treatment can cause long-term sequelae; meanwhile, patients will be confronted with the antimicrobial resistance and side effects.

Chinese patent medicine as a supplement is used to treat PID with satisfactory clinical efficacy.

This study evaluated the efficacy and safety of Fuke Qianjin (FKQJ) combined with antibiotics in the treatment of PID.

Methods.

Eight electronic databases and other resources were searched to make a collection of the randomized controlled trials (RCTs) from 1990 to 2019.

The RCTs contrasting the effect of FKQJ combined with antibiotics regimens and antibiotics alone in reproductive women with PID were included.

The antibiotics regimens are all recommended by the guidelines.

Two reviewers independently screened the studies, extracted the data, and assessed the methodological quality of the included studies.

Then, the meta-analyses were performed by RevMan 5.

3 software if appropriate.

Results.

Twenty-three RCTs (2527 women) were included in this review.

The evidence showed that FKQJ combined with antibiotics improved the markedly effective rate compared to antibiotics alone group (RR = 1.38, 95% CI 1.27 to 1.49, I2 = 42%), shortened the improvement time of low abdominal pain (MD = −1.11, 95% CI −1.39 to −0.84, I2 = 38%), and increased the rate of lower abdominal pain improvement (RR = 1.35, 95% CI 1.19 to 1.55, I2 = 0).

The implementation of adjuvant reduced the recurrent rate compared with antibiotics alone (RR = 0.27, 95% CI 0.13 to 0.56, I2 = 0%).

Conclusions.

Based on available evidence, FKQJ combined with antibiotics therapy have certain outcomes on increasing the markedly effective rate, decreasing the recurrent rate compared with antibiotics alone group.

This therapy appears to improve lower abdominal pain and curtail the relief time.

Due to the low quality and the risk of bias, any high-quality evidence or longer follow-up period should be advisable and necessary in the future.